Bayer, J&J's bid to further widen use of Xarelto hits snag


Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit. The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal, Germany February 24, 2014.



from Biotech News